Su Pen-Hua, Chen Jia-Yuh, Su Chi-Ming, Huang Tzu-Ching, Lee Hong-Shen
Department of Pediatrics and Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Pediatr Int. 2003 Dec;45(6):665-70. doi: 10.1111/j.1442-200x.2003.01797.x.
Patent ductus arteriosus (PDA) is commonly found in very low-birthweight (VLBW) infants. The presence of respiratory distress syndrome (RDS) is also associated with increased frequency of significant PDA. Intravenous indomethacin has been used to treat and to prevent PDA in premature infants since 1976. However, concern remains regarding the safety of indomethacin, which affects renal, gastrointestinal and cerebral perfusion. Intravenous ibuprofen has recently been used to treat and to prevent PDA premature infants with PDA without reducing cerebral blood flow or affecting intestinal or renal hemodynamics. The aim of the present study is to compare intravenous ibuprofen and indomethacin with regard to efficacy and safety for the early treatment of PDA in preterm infants.
A total of 63 preterm infants with RDS who had a birthweight of < or =1500 g and gestational age of < or =32 weeks, were enrolled in the present study. All patients were treated with nasal continuous positive airway pressure with additional oxygen supply in inspired air>30%, or with mechanical ventilation. The patients' serum platelet counts were>100,000/uL, and serum creatinine values were <1.5 mg/dL. There were no 3-4 grade intraventricular hemorrhages before randomization, and all patients were aged 2-7 days and had echo-cardio-graphic evidence of significant PDA. Patients were randomized into two groups: the first group of neonates (group A, n = 32) received intravenous ibuprofen lysine 10 mg/kg, followed by 5 mg/kg after 24 and 48 h; the second group (group B, n = 31) received intravenous indomethacin 0.2 mg/kg every 12 h for three doses.
Patent ductus arteriosus closed in 27 patients from the ibuprofen group (84.4%) and in 25 patients from the indomethacin group (80.6%). PDA reopened in three patients from the ibuprofen group (9.4%) and in three patients from the indomethacin group (9.7%). One patient in the ibuprofen group and two patients in the indomethacin group required ductal ligation. Serum creatinine and blood urea nitrogen (BUN) concentrations were lower in the ibuprofen group than in the indomethacin group. Urine output and creatinine clearance values were higher in the ibuprofen group than in the indomethacin group.
Ibuprofen therapy is as efficacious as indomethacin for the treatment of PDA in preterm infants. Infants treated with ibuprofen have higher creatinine clearance and urine output and lower serum creatinine and BUN values than infants treated with indomethacin.
动脉导管未闭(PDA)在极低出生体重(VLBW)婴儿中很常见。呼吸窘迫综合征(RDS)的存在也与显著PDA的发生率增加有关。自1976年以来,静脉注射吲哚美辛一直用于治疗和预防早产儿的PDA。然而,对于影响肾脏、胃肠道和脑灌注的吲哚美辛的安全性仍存在担忧。静脉注射布洛芬最近已被用于治疗和预防患有PDA的早产儿,且不会减少脑血流量或影响肠道或肾脏血流动力学。本研究的目的是比较静脉注射布洛芬和吲哚美辛在早产儿早期治疗PDA方面的疗效和安全性。
本研究共纳入63例出生体重≤1500g、胎龄≤32周的患有RDS的早产儿。所有患者均接受经鼻持续气道正压通气,并在吸入空气中额外供氧>30%,或接受机械通气。患者的血清血小板计数>100,000/μL,血清肌酐值<1.5mg/dL。随机分组前无3 - 4级脑室内出血,所有患者年龄在2 - 7天,且有超声心动图证实的显著PDA。患者被随机分为两组:第一组新生儿(A组,n = 32)静脉注射赖氨酸布洛芬10mg/kg,24小时和48小时后再注射5mg/kg;第二组(B组,n = 31)每12小时静脉注射吲哚美辛0.2mg/kg,共注射三剂。
布洛芬组27例患者(84.4%)的动脉导管未闭闭合,吲哚美辛组25例患者(80.6%)的动脉导管未闭闭合。布洛芬组3例患者(9.4%)和吲哚美辛组3例患者(9.7%)动脉导管未闭重新开放。布洛芬组1例患者和吲哚美辛组2例患者需要进行导管结扎。布洛芬组的血清肌酐和血尿素氮(BUN)浓度低于吲哚美辛组。布洛芬组的尿量和肌酐清除率值高于吲哚美辛组。
布洛芬治疗早产儿PDA与吲哚美辛疗效相当。与接受吲哚美辛治疗的婴儿相比